Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Novelix Pharmaceuticals Ltd. significantly underperforms compared to its peers across all key metrics. With negative growth, high valuation ratios, and low profitability, it presents a concerning picture for investors. In contrast, Adani Enterprises and Redington stand out as strong performers in terms of growth and profitability.
Strong revenue growth (1.53% YoY), low PE of 43.53, and solid ROE of 9.48%
Highest revenue growth (12.56% YoY), solid profitability with ROE of 17.12% and low PE of 13.20